Results 11 to 20 of about 622,361 (248)
Designing ecologically optimized pneumococcal vaccines using population genomics. [PDF]
Nat Microbiol, 2020 Colijn C, Corander J, Croucher NJ.
europepmc +2 more sources
Pneumococcal whole-cell and protein-based vaccines: changing the paradigm
Expert Review of Vaccines, 2017 Introduction: Epidemiologic evaluations of Streptococcus pneumoniae nasopharyngeal (NP) colonization and pneumococcal disease suggest that newer serotypes in future formulations of pneumococcal conjugate vaccines (PCVs) are needed and there may need to ...
Michael E. Pichichero
doaj +2 more sources
Immunogenicity of pneumococcal vaccines in comorbid autoimmune and chronic respiratory diseases [PDF]
Human Vaccines & Immunotherapeutics, 2019 Streptococcus pneumoniae causes pneumonia, meningitis, otitis media, and bacteremia. The mortality and morbidity of invasive pneumococcal disease are high among adults aged >65 years or those with underlying chronic or immunosuppressive conditions.
Koji Kuronuma, Hiroki Takahashi
doaj +2 more sources
Effectiveness of pneumococcal vaccine [PDF]
The Lancet, 1998 Åke Örtqvist +2 more
openalex +4 more sources
Journal of Medical Microbiology, 1996 Streptococcus pneumoniae, commonly termed the pneumococcus, is a major pediatric pathogen both in developed and developing countries. Despite the availability of multiple antimicrobials to which this organism is susceptible, it continues to cause significant morbidity and mortality. Recognition of the limitations of antimicrobial therapy in controlling
G, Peter, J O, Klein
openaire +4 more sources
Биопрепараты: Профилактика, диагностика, лечение, 2021 Streptococcus pneumoniae infection is the most common cause of high morbidity and mortality among children under 5 years of age, immunocompromised people, and the elderly.
M. V. Savkina +6 more
doaj +1 more source
Strengths and weaknesses of pneumococcal conjugate vaccines
Glycoconjugate Journal, 2023 Multivalent vaccines addressing an increasing number of Streptococcus pneumoniae types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years.
F. Micoli +4 more
semanticscholar +1 more source
Postgraduate Medical Journal, 1997 Summary Streptococcus pneumoniae is a frequent cause of pneumonia and meningitis. This article looks at the pneumococcal vaccine, its uses, efficacy, and adverse effects and how vaccination may be improved. We also look at the role of the new conjugate vaccines.
K L, Hattotuwa, C R, Hind
openaire +2 more sources
Emerging Infectious Diseases, 2022 We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe.
G. Hanquet +29 more
semanticscholar +1 more source
Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection
Vaccines, 2020 Streptococcus pneumoniae is a major pathogen causing pneumonia with over 2 million deaths annually, especially in young children and the elderly. To date, at least 98 different pneumococcal capsular serotypes have been identified. Currently, the vaccines
Malihe Masomian +3 more
doaj +1 more source